PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer. (2026). Journal of Evidence-Based Medical Research, 2(03), 58-69. https://doi.org/10.66687/jebmr.2.03.2026.43